|
Mar 14
|
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
|
|
Mar 14
|
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 13
|
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
|
|
Mar 13
|
Q4 2024 Nektar Therapeutics Earnings Call
|
|
Mar 13
|
Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Mar 13
|
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Mar 12
|
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
|
|
Mar 12
|
Nektar: Q4 Earnings Snapshot
|
|
Mar 12
|
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 12
|
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 24
|
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
|
|
Feb 24
|
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
|
|
Feb 10
|
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
|
|
Jan 4
|
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership
|
|
Sep 25
|
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
|
|
Jun 12
|
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
|
May 10
|
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
|
|
May 10
|
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
|
May 10
|
Q1 2024 Nektar Therapeutics Earnings Call
|